Jordana Joy

Articles by Jordana Joy

Alice Epitropoulos, MD, FACS, and John Hovanesian, MD

FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia

ByJordana Joy,Lynda Charters,Sheryl Stevenson

October 16th 2026

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.

What is the biggest barrier to eye care access worldwide?

ByMagdalena Stec, OD, FAAO,Noreen Shaikh, OD, MEd, FAAO,Elaine Chen, OD, FAAO, FSLS,Obinwanne Chukwuemeka Jr., OD, MOptom, Dipl AAO, FAAO, FLVPEI, FSLS,Rima Khankan, PhD, MS,Huizi Yin, OD, FAAO,Brenda Bohnsack, MD, PhD,Anita Shiva,Jordana Joy

October 8th 2026

A handful of eye care providers spoke on the factors that have led to a lack of eye care access for World Sight Day.

FDA Advisory Committee to review SYD-101 for pediatric myopia October 30

ByJordana Joy

September 24th 2026

The meeting will include an Open Public Hearing.

FDA accepts NDA for bimatoprost grenod in open-angle glaucoma and OHT

ByJordana Joy

August 27th 2026

The agency assigned a PDUFA target action date of April 30, 2027.

Jordana Joy

Articles by Jordana Joy

FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia

What is the biggest barrier to eye care access worldwide?

FDA Advisory Committee to review SYD-101 for pediatric myopia October 30

FDA accepts NDA for bimatoprost grenod in open-angle glaucoma and OHT

Latest Updated Articles

Trending on Eye Care Network - Ophthalmology Times

Duravyu misses wet AMD end point again as EyePoint pivots to DME

Oculis completes randomization in PREDICT-1, the first genotype-guided registrational trial in dry eye disease

CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease

(FAQ) Inflammatory Eye Disease Week: What clinicians should know

Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA